Legal & General Group Plc Reduces Stake in Amedisys, Inc. (NASDAQ:AMED)

Legal & General Group Plc lessened its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 5.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 68,311 shares of the health services provider’s stock after selling 3,615 shares during the quarter. Legal & General Group Plc owned 0.21% of Amedisys worth $6,202,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of AMED. Invesco Ltd. grew its position in shares of Amedisys by 5.8% during the 4th quarter. Invesco Ltd. now owns 90,847 shares of the health services provider’s stock valued at $8,248,000 after acquiring an additional 4,942 shares during the period. Wells Fargo & Company MN increased its position in Amedisys by 4.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,161 shares of the health services provider’s stock worth $650,000 after buying an additional 323 shares in the last quarter. Resona Asset Management Co. Ltd. bought a new position in shares of Amedisys in the fourth quarter worth about $535,000. ExodusPoint Capital Management LP purchased a new position in shares of Amedisys during the 4th quarter valued at about $356,000. Finally, Cinctive Capital Management LP bought a new position in shares of Amedisys during the 4th quarter valued at approximately $8,155,000. Institutional investors own 94.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on AMED. Stephens reaffirmed an “equal weight” rating and set a $101.00 price target on shares of Amedisys in a report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Amedisys in a report on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Performance

Shares of AMED stock opened at $91.76 on Monday. Amedisys, Inc. has a 52-week low of $82.15 and a 52-week high of $98.95. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a market cap of $3.01 billion, a PE ratio of 36.41, a price-to-earnings-growth ratio of 1.78 and a beta of 0.89. The business has a 50-day simple moving average of $92.14 and a 200-day simple moving average of $91.86.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. On average, equities analysts expect that Amedisys, Inc. will post 4.4 EPS for the current year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.